Supernus Pharmaceuticals, Inc. (SUPN) News
Track canonical SquawkNews coverage tagged to SUPN, Supernus Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
SUPN: Strong CNS portfolio growth and a strategic merger position the company for accelerated innovation
The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, a successful postpartum depression launch, and a promising pipeline. The planned Indivior merger aims to accelerate di
MNA | Sep 09, 2026, 08:13 PM UTC
H
SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion
The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, overcoming supply challenges and expanding through strategic M&A. The pipeline features innovative treatments for depr
MNA | Sep 09, 2026, 07:39 PM UTC
L
SUPN - Supernus Pharmaceuticals to Participate in September Investor Conferences
SUPN - Supernus Pharmaceuticals to Participate in September Investor Conferences
EQUITY | Sep 02, 2026, 08:30 PM UTC
L
Top 3 Health Care Stocks You'll Regret Missing This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Aug 04, 2026, 10:04 AM UTC
L
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) and Indivior Pharmaceuticals Inc. (NASDAQ: INDV ) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system (CNS) biopharmace
EARNINGS | Aug 03, 2026, 02:44 PM UTC
H
Supernus, Indivior Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader
MNA | Aug 03, 2026, 12:26 PM UTC
H
Indivior Buys Supernus
Indivior acquires Supernus in stock deal
MNA | Aug 03, 2026, 10:35 AM UTC
L
SUPN - Supernus Announces Second Quarter 2026 Financial Results
SUPN - Supernus Announces Second Quarter 2026 Financial Results
EARNINGS | Aug 03, 2026, 10:35 AM UTC
L
SUPN +12%, INDV +2% premarket after M&A headlines
SUPN +12%, INDV +2% premarket after M&A headlines
MNA | Aug 03, 2026, 10:34 AM UTC
H
SUPN, INDV Agree Merger
SUPN and INDV agree to merge
MNA | Aug 03, 2026, 10:33 AM UTC
H
Supernus Pharmaceuticals Merges With Indivior
Supernus stockholders get Indivior shares
MNA | Aug 03, 2026, 10:31 AM UTC
H
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significa
SUPN INDV Supernus Pharmaceuticals and Indivior Pharmaceuticals to merge, creating a diversified Cns biopharmaceutical leader with significant scale Supernus Pharmaceuticals Inc - combined entity to be named Supernus, In
MNA | Aug 03, 2026, 10:31 AM UTC
H
Supernus, Indivior to Merge
Supernus and Indivior merge to create CNS biopharmaceutical leader
MNA | Aug 03, 2026, 10:30 AM UTC